- •CONTENTS
- •Contributors
- •Preface
- •I Components of Angiogenic Cascades
- •1. Introduction and Historical Perspective
- •2. The Semaphorins
- •3. The Plexin Receptor Family
- •4. The Neuropilins
- •5. Vascular Endothelial Growth Factors and Their Receptors
- •6. Signal Transduction by Neuropilins
- •7. The Role of the Neuropilins in the Regulation of Vasculogenesis and Angiogenesis
- •8. Modulation of Angiogenesis by Semaphorins that Bind Directly to Plexins
- •Acknowledgments
- •References
- •1. Introduction
- •1.1. Eph receptor domain structure
- •1.2. The ephrin domain structure
- •2. Effects on Vascular Cell Behavior and Signaling Pathways
- •2.1. Ephrin-A1 and EphA2
- •2.2. Ephrin-A1 and EphA4
- •2.3. Ephrin-B and EphB
- •2.3.1. EphB forward signaling
- •2.3.2. Ephrin-B reverse signaling
- •2.4. Crosstalk with other angiogenic pathways
- •3. Endothelial Cell Fate
- •4. Angiogenic Remodeling of Embryonic Blood Vessels
- •4.1. Ephrin-A1 and EphA receptors
- •4.2. EphB4 and Ephrin-B2
- •4.3. Other EphB receptors and Ephrin-Bs
- •5. Lymphatic Vessels
- •6. Adult Vasculature
- •6.1. Quiescent vasculature
- •6.2. Physiological angiogenesis
- •6.3. Inflammation and wound healing
- •6.4. Tumor angiogenesis
- •6.4.1. Ephrin-A1 and EphA2
- •6.4.2. Ephrin-B2 and EphB4
- •8. Perspectives
- •Acknowledgments
- •References
- •1. Introduction
- •2. Molecular Mechanisms
- •3. Role in Vascular Development
- •4. FGFs in Tumor Angiogenesis
- •5. Role of FGFs in Developmental and Tumor Lymphangiogenesis
- •7. Conclusion
- •Acknowledgments
- •References
- •1. The NPY System
- •2. NPY as a Growth Factor for Vascular Cells
- •3. DPPIV: A Molecular Switch of the NPY Angiogenic System
- •4. Downstream Mediators of NPY Actions
- •5. NPY in Revascularization of Ischemic Tissues
- •6. NPY in Wound Healing
- •7. NPY in Adipose Tissue Growth and Obesity
- •8. NPY in Retinopathy
- •10. NPY in Tumor Angiogenesis
- •11. NPY-Mediated Angiogenesis and Neurogenesis
- •References
- •1. Introduction
- •2. Historical Perspective
- •3.1. The HSPG core proteins
- •3.2. The structure of the HS chain
- •3.3. The biosynthesis of HS
- •3.4. The post-synthetic processing of HSPGs
- •4. Evolution of HSPGs
- •5. HSPGs in Development
- •6. HSPG Modulation of Ligand-Receptor Interactions
- •6.2. HSPG co-receptors confer unique regulatory properties
- •6.2.1. Co-receptors engender stoichiometric control of signaling
- •6.2.2. The effects of glycanation
- •6.2.3. HS sequence motifs regulate signaling
- •7. HSPGs Enable Global Control of EC Phenotype
- •8. Future Therapeutic Directions
- •9. Conclusions
- •References
- •II Angiogenic Regulators
- •1. Introduction: Blood Vessels and Nerves Use Similar Guidance Cues
- •2. Semaphorin Signaling
- •2.1. Neuropilins
- •2.2. Plexins
- •3. Ephrins and Eph Signaling
- •3.1. Forward signaling
- •3.2. Reverse signaling
- •4. Netrin and Slit Signaling
- •5. Open Questions
- •References
- •1. Oxygen Homeostasis: Phylogeny, Ontogeny, Physiology, and Pathobiology
- •5. Control of Angiogenesis and Arteriogenesis by HIF-1
- •6. Control of Tumor Angiogenesis by HIF-1
- •References
- •1. Introduction
- •2. Reactive Oxygen Species (ROS) in the Vasculature
- •3. ROS and Angiogenesis
- •4. NAD(P)H Oxidase: A Major Source of ROS in the Vasculature
- •5. Role of NAD(P)H Oxidase in Angiogenesis
- •6. ROS as Signaling Molecules in Angiogenesis
- •8. Conclusion
- •References
- •1. Introduction
- •2. Assessing Coronary Angiogenesis and Arteriogenesis
- •3. Pressure Overload-Induced Hypertrophy
- •4. Volume Overload-Induced Cardiac Hypertrophy
- •5. Thyroxine-Induced Hypertrophy
- •6. Hypoxia-Induced Hypertrophy
- •7. Exercise-Induced Hypertrophy
- •8. Myocardial Infarction-Induced Hypertrophy
- •9. Modulators of Angiogenesis During Hypertrophy
- •10. Stimuli of Angiogenesis During Hypertrophy
- •11. Summary
- •References
- •1. Introduction
- •2. Coronary Resistance
- •3. Regulation of Coronary Microvascular Tone
- •3.1. Intrinsic and extrinsic vasomotor control
- •3.2. Role of the endothelium
- •3.3. Role of metabolism and autoregulation
- •3.4. Flow-induced dilation
- •3.5. Neurohumoral influence on microcirculation
- •3.6. Intrinsic myogenic tone
- •3.7. Impact of extravascular and humoral factors on the coronary microcirculation
- •3.8. Role of venules in coronary resistance
- •4. Endothelial Factors in Vascular Growth and Response to Injury
- •5. Impact of Disease States on Coronary Circulation
- •6. The Coronary Microcirculation in Hypertophic States
- •7. Summary
- •References
- •III Clinical Applications
- •1. Kinase Inhibition and Tumor Angiogenesis
- •2. Major Angiogenesis Factors and Receptors
- •2.1. VEGF signaling
- •3. Further Angiogenesis-Related Signaling
- •4. Need for Selectivity of Anti-Angiogenic Kinase Inhibitors
- •5. Kinase Inhibitors in Clinical Development
- •5.1. BAY 43-9006 (Sorafenib)
- •5.2. PTK/ZK (Vatalanib)
- •5.3. SU11248 (Sunitinib)
- •5.9. BIBF 1120
- •5.10. Chir-258
- •5.12. SU5416 (Semaxinib)
- •6. Challenges and Future Directions
- •Acknowledgments
- •References
- •1. Introduction
- •2. Concepts and Rationales
- •3. Strategy
- •4. Clinical Trials
- •4.1. Growth factor-based, angiogenic approach
- •4.2. Cell therapy-based, vasculogenic and paracrine approach
- •5. Issues Regarding Current Strategy
- •5.1. Choice of biological agent
- •5.2. Pharmacokinetics and delivery mode
- •5.3. Monitoring of neovascularization
- •5.4. Study design
- •6. Emerging Concepts of Therapeutic Angiogenesis
- •6.1. Neovascularization responsiveness
- •6.2. Genetic determination of neovascularization
- •7. Future Prospective
- •8. Summary
- •References
- •1. Hepatocyte Growth Factor in Cardiovascular System
- •2. HGF Signaling in Endothelial Cells
- •3. Angiogenic Therapy for Ischemic Peripheral Arterial Diseases
- •4. Clinical Trial in PAD
- •5. HGF Gene Therapy for Myocardial Ischemia
- •6. HGF Gene Therapy for Restenosis After Angioplasty
- •7. Next Five Years Perspective — Future Direction of HGF Therapy
- •Acknowledgments
- •References
- •1. Endothelial Nitric Oxide in Health and Disease
- •1.1. Nitric oxide synthases
- •1.2. Physiological role of endothelial NO (“EDNO”)
- •1.3. Endothelial NO-deficiency in cardiovascular diseases
- •1.4. Therapeutic restoration of endothelial NO production in cardiovascular diseases
- •2. Nitric Oxide and Angiogenesis
- •2.2. Tumor angiogenesis and NO
- •2.3. Evidence in cultured endothelial cells and in rabbit cornea
- •2.4. Role of NO in post-ischemic revascularization
- •2.6. Molecular mechanisms
- •3. NOS Gene Transfer
- •3.1. Gene delivery vectors
- •3.2. NOS-III gene transfer
- •3.3. NOS-II gene transfer
- •4.1. Impaired angiogenesis and arteriogenesis in patients with critical limb ischemia
- •4.2.1. NOS-III-KO mice
- •4.2.2. NOS-III transgenic mice
- •4.2.3. Wild-type NOS-III gene transfer in normal rats
- •4.5.1. Plasmid delivery of the NOS1177D gene
- •4.5.2. Adenoviral delivery of the NOS1179D gene
- •6. Conclusions
- •Acknowledgments
- •References
- •Index
296 B. Ramlawi et al.
Other neurotransmitters that act on the coronary circulation include neuropeptide Y. NPY is mainly released with norepinephrine as a cotransmitter from sympathetic post-ganglionic nerve terminals upon intense sympathetic activation.2,33 Intracoronary application of NPY markedly decreases coronary flow, producing myocardial ischemia without large coronary artery constriction.34,35 These results point to its potent and specific constrictor effects on coronary microvessels. Also, substance P, a potent vasodilator whose effect is dependent on the endothelium, is contained in perivascular nerve fibers and sensory ganglia.36
3.6. Intrinsic myogenic tone
Myogenic contraction is observed when applying luminal pressure to microvessels causing a development of intrinsic vascular tone as shown by elevated wall tension or a decrease in vessel diameter. The coronary microcirculation, like other vascular beds, possesses this intrinsic myogenic tone response which also contributes to maintaining basal vascular tone and autoregulation.37 Myogenic microvascular control is endothelium-independent, and is likely to play a critical role in determining the basal tone and maintaining the intraluminal pressure of the downstream exchange vessels within a physiological level.38,39 Myogenic responses to increases in pressure are greater in subepicardial microvessels than in vessels from the subendocardium. Also, myogenic tone may be reduced during inflammatory states where there is increased expression of iNOS causing altered myocardial perfusion. Increases in myogenic tone, which occur during stretch of vascular smooth muscle, are associated with an increase in inositol-1,4,5-trisphosphate, presumably due to activation of phospholipase C.37,40,41 Also, the myogenic tone mediator 20-HETE produces constriction of vascular smooth muscle by promoting Ca2+-activated K+ (BK) channel inhibition. This induces depolarization and increases levels of [Ca2+]i This effect is likely caused by activation of L-type Ca2+ channels and/or the activation of PKC and inhibition of the Na-K-ATPase.42 Other mediators likely involved in the myogenic tone response include mitogen activated protein (MAP) kinases and Rho protein. The downstream mediator
Regulation of Coronary Vascular Tone and Microvascular Physiology |
297 |
Rho kinase may modulate myogenic tone by regulation of the actin cytoskeleton. One potential therapeutic agent for treatment of hypertension and coronary spasm is the use of Rho kinase inhibitors. A summary of possible mechanisms of myogenic tone are summarized in Fig. 9.
3.7.Impact of extravascular and humoral factors on the coronary microcirculation
In the setting of pathologic processes such as ischemia leading to decreased tissue compliance or increased tissue edema, extravascular forces play an especially important role. For example, collateral perfusion is particularly sensitive to changes in heart rate (more frequent extravascular compression) and ventricular diameter (stretch).6,43 The coronary circulation is particularly unique in that it is exposed to a large number of extravascular forces produced by contraction of adjacent myocardium and intraventricular pressures. Of relevance to the concept of extravascular forces is the idea that these may collapse coronary vessels under certain circumstances. Of note, flow through the epicardial coronary arteries halted when aortic pressure fell to values ranging from 25 to 50 mmHg raising the possibility that extravascular forces may be sufficiently high to collapse vessels when intraluminal pressure declines to values below this critical value.44 Flow in the coronary microcirculation continued even when the arterial driving pressure was minimally higher than coronary venous pressure. Based on modeling and various experimental interventions, it was determined that the decrease of antegrade blood flow in larger upstream vessels associated with continued forward flow in microvessels was likely due to capacitance in the coronary circulation.45 Kanatsuka and colleagues used a floating microscope to visualize epicardial capillaries and were able to show that red cells continued to flow, even after perfusion had stopped in the more proximal vessels.46 Using this approach, they were able to show that the pressure at which flow stops in the epicardial coronary microvessels was only a few mmHg higher than right atrial pressure.46 Also, when ventricular diastolic pressure is high, vessels deeper in the subendocardium may be made to collapse by pressure transmitted from
298 B. Ramlawi et al.
Fig. 9. Schematic illustration for the possible mechanisms of the myogenic constriction (A) and its compensatory mechanisms (B). DG, Diacylglycerol; 20-HETE, 20hydroxyeicosatetraenoic acid. (Adapted from Ref. 2.)
Regulation of Coronary Vascular Tone and Microvascular Physiology |
299 |
the ventricular chamber. In contrast, coronary epicardial vessels do not close at any pressure. It therefore seems likely that the concept of “critical closing pressure” is not applicable to all vessels in the coronary circulation.
The coronary microcirculation responds to humoral agents differently depending on vessel size and location. Endothelin-1 produces vasoconstriction when administered to the adventitial surface of coronary microvessels. The degree of constriction produced by endothelin- 1 is inversely related to the size of the vessels. In contrast, when endothelin-1 is administered intra-arterially, vasodilation occurs presumably via release of nitric oxide.29,31 Also, serotonin constricts vessels >100 µm in diameter whereas it causes vasodilation of smaller arteries.47 Vasopressin, on the other hand, produces greater constriction of microvessels less than 100 µm in diameter than it produces in larger microvessels.47,48 In the larger epicardial coronary arteries, vasopressin causes predominantly vasodilation.
3.8. Role of venules in coronary resistance
Vasomotor regulation is differentially controlled between the venous and arterial microcirculations and certain reactions to pathologic stimuli occur preferentially on one side of the capillary bed. Therefore, consideration of the venous circulation apart from the arterial circulation is needed. Venules have a considerable importance under conditions of vascular dilation such as during exercise, metabolic stress or during reperfusion after myocardial ischemia.9 The venous circulation may influence myocardial stiffness and relaxation properties of the heart. Veins also respond differently to agonists and neuronal stimulation compared to arteries in the same vascular bed.31,49 Also, venules are the initiating site of neutrophil adherence and transmigration whereas arterioles seldom manifest these initial changes in the inflammatory response.50 While ischemia-reperfusion has been determined to cause endothelial dysfunction in veins , under similar conditions, arterioles appear to be more susceptible to a reduction in endothelium-dependent relaxation than are coronary venules, despite the fact that leukocytes preferentially adhere to venular as compared to arterial endothelial
